

CLARK HILL

Charles R. Berry
T: 480.684.1302
F 480.684.1188
Email: cberry@clarkhill.com

Clark Hill PLC
14850 N. Scottsdale Road
Suite 500
Scottsdale, AZ 85254
T 480.684.1100
F 480.684.1199

clarkhill.com

September 19, 2016

OTC Markets Group Inc.
304 Hudson Street, Third Floor
New York, NY 10013

Re: Bourque Industries, Inc.-Attorney Letter

Ladies and Gentlemen:

This Attorney Letter (this “**Letter**”) is being provided to OTC Markets Group Inc., a Delaware corporation (“**OTC Markets**”) by the law firm of Clark Hill PLC (“**Clark Hill**”), which has been retained by Bourque Industries, Inc., a Nevada corporation (the “**Company**”) to provide advice with respect to information publicly disclosed by the Company and posted through the OTC Disclosure & News Service. Clark Hill understands that this Letter will be posted by the Company, and will be published, accompanying the Company’s disclosure, in the OTC Disclosure & News Service. OTC Markets is entitled to rely on this Letter in determining whether the Company has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933.

Clark Hill is a law firm with headquarters in the United States, and the lawyer executing this letter (sometimes referred to as the “**Signer**”) is a U.S. resident. Clark Hill has been retained by the Company for the purpose of rendering this Letter and handling other related matters. Currently, Clark Hill is serving as special disclosure counsel for the Company, and has been retained also for the purpose of reviewing the current information supplied by the Company. This Letter is submitted in connection with the performance of these obligations.

The Signer is licensed to practice law in the State of Arizona and the Federal Courts of the United States. The Signer is allowed to practice before the United States Securities and Exchange Commission (the “**SEC**”), and has never been prohibited from practicing before the SEC. This Letter applies to the United States of America and all jurisdictions therein. As to matters of fact, we have relied on information obtained from public officials, officers of the Company and other sources, and all such sources are believed to be reliable. We have examined such corporate records, filings and other documents and such questions of law, as we have considered necessary or appropriate for purposed of rendering this Letter.

On September 16, 2015, we reviewed the disclosure entitled Bourque Industries, Inc. OTC Pink Basic Disclosure Guidelines Report, Year Ended May 31, 2016 (Unaudited) (the "**Report**") published by the Company with OTC Disclosure & News Service September 17, together with the Bourque Industries, Inc. Annual Report for the Fiscal Year Ended May 31, 2016, including the Company's Unaudited Financial Statements for the Fiscal Years Ended May 31, 2016, 2015, and 2014. These documents contain all the information required to be filed by the Company at year-end for its fiscal year ending May 31, 2016, as set forth in §2 of the Guidelines for Providing Adequate Current Information, §§1-9 of the Company's Continuing Disclosure Obligations. The Report and the related documents were filed in connection with the Company's ongoing reporting obligations with the OTC Disclosure & News Service. We also reviewed other materials published by the Company with OTC Markets, including interim and periodic reports, attorney's letters and supplemental information, as well as SEC filings, including a Schedule 13G (Amendment No. 2) filed February 13, 2015 by Ironridge Global IV, Ltd. The Report and the other documents described in this paragraph are collectively referred to as the "**Information**".

The Information: (i) constitutes "adequate current public information" concerning the Company and "is available" within the meaning of Rule 144(c)(2) under the Securities Act, (ii) includes all of the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the Company's common stock under Rule 15c2-11, (iii) complies as to substance with the OTC Markets Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otcm Markets.com, and (iv) is posted in the OTC Disclosure & News Service.

The person responsible for preparing the financial statements contained in the Report and other current disclosures made by the Company is Charmaine S. Berry, who is qualified to prepare such financial statements by virtue of her professional experience and education. The Company's financial statements for the two most recent fiscal years have **not** been audited.

The Company's transfer agent is American Registrar & Transfer Co., Inc., (the "**Agent**"). The Agent is registered with the SEC. The Agent confirmed by email dated July 16, 2015 that the number of issued and outstanding common shares of the Company was 955,865,190.

In addition:

A. We have (i) personally met or conferred with management and a majority of directors of the Company, (ii) reviewed the Information, and (iii) discussed the Information with management and a majority of directors.

B. To the best of our knowledge, after inquiry, neither the Company, nor any 5% holder of its securities (with the exception of Ironridge, which as described in the Report, was sued by the SEC) is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

We have no reason to believe that, at the time any public information was published by the Company, the information contained untrue statements of material fact or omitted to state a material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading.

Based on available information, we have a reasonable belief that the Company has made adequate current public information available within the meaning of Rule 144(c)(2) under the Securities Act of 1933.

This Letter is being furnished solely to OTC Markets Group, and may not be relied upon, used, circulated, quoted or otherwise referred to by OTC Markets Group for any other purpose without prior express written permission of Clark Hill. Except as provided for in the preceding sentence, this Letter may not be relied upon by any individual, partnership, limited liability company, joint venture, corporation, trust, unincorporated organization, or other entity, for any purpose whatsoever, without prior express written permission of Clark Hill.

Very truly yours,



Charles R. Berry

llg/CRB

203277252.4 51124/188033

CLARK HILL